SCHEMBL26258706

SCHEMBL26258706

Cc1ccc2c(c1)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)O)c1nnc(C)n1-2

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 19/20 0.79
HDAC1 Q13547 2/20 0.63
HDAC2 Q92769 2/20 0.63
SMCHD1 A6NHR9 1/20 0.63
MYO1G B0I1T2 1/20 0.63
AIP O00170 1/20 0.63
AP3B1 O00203 1/20 0.63
PSMD11 O00231 1/20 0.63
CDC7 O00311 1/20 0.63
SAP18 O00422 1/20 0.63
KPNA3 O00505 1/20 0.63
PPP6C O00743 1/20 0.63
TCERG1 O14776 1/20 0.63
UBE2L6 O14933 1/20 0.63
PPP1R12A O14974 1/20 0.63
U2SURP O15042 1/20 0.63
SETD1A O15047 1/20 0.63
ARPC1B O15143 1/20 0.63
POLR1C O15160 1/20 0.63
OGT O15294 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9998870 0.91 BRD4 (0.78) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL9998756 0.90 BRD4 (0.77) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL26258661 0.90 BRD4 (0.65) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL9998786 0.89 BRD4 (0.75) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL26258704 0.89 BRD4 (0.83) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL7903005 0.89 BRD4 (0.75) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL17451427 0.89 BRD4 (1.00) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL1820357 0.89 BRD4 (1.00) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL14756416 0.89 BRD4 (1.00) BRD4HDAC1HDAC2SMCHD1MYO1G
SCHEMBL25269620 0.88 BRD4 (0.73) BRD4HDAC1HDAC2SMCHD1MYO1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2023-09-14 US disclosed
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM XIAP, CUL4A, CUL1 BRD4 331/4885HDAC1 957/4885HDAC2 2749/4885
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE BET1, BRD4, PHKB BRD4 2/4885HDAC1 158/4885HDAC2 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.